Debio 1452

Drug Profile

Debio 1452

Alternative Names: AFN 1252; AFN-12520000; API 1252

Latest Information Update: 29 Jul 2015

Price : $50

At a glance

  • Originator Affinium Pharmaceuticals
  • Developer Debiopharm Group
  • Class Anti-infectives; Small molecules
  • Mechanism of Action Enoyl-ACP reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Skin and soft tissue infections
  • Phase I Bacterial infections

Most Recent Events

  • 29 Jul 2015 Phase II development for Skin and soft tissue infections is ongoing
  • 11 Feb 2014 Debiopharm Group acquires Affinium Pharmaceuticals
  • 12 Nov 2013 Antimicrobial & pharmacodynamics data from preclinical studies in Bacterial infections released by Affinium Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top